Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    887 result(s) found for: Bone marrow biopsy. Displaying page 8 of 45.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2016-005019-42 Sponsor Protocol Number: ET16-132 Start Date*: 2018-02-14
    Sponsor Name:Centre Léon Bérard
    Full Title: A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas pati...
    Medical condition: localised and operable soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005325-12 Sponsor Protocol Number: CFZ014 Start Date*: 2015-08-10
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) PL (Completed) GR (Completed) SE (Completed) FI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-000941-10 Sponsor Protocol Number: CLI24-001 Start Date*: 2020-07-02
    Sponsor Name:Menarini Ricerche S.p.A
    Full Title: A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia
    Medical condition: Acute Myeloid Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003947-27 Sponsor Protocol Number: TAK-981-1002 Start Date*: 2021-07-04
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: An Open Label, Dose-Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumor...
    Medical condition: Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    27.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005008-32 Sponsor Protocol Number: ICORG13-17 Start Date*: 2014-07-16
    Sponsor Name:Cancer Trials Ireland
    Full Title: A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma
    Medical condition: Newly diagnosed multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001933-16 Sponsor Protocol Number: 26866138PCR2002 Start Date*: 2007-03-13
    Sponsor Name:Christos N. Papandreou
    Full Title: "A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy"
    Medical condition: Treatment of patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy.
    Disease:
    Population Age: Gender: Male
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004418-32 Sponsor Protocol Number: U31402-A-U202 Start Date*: 2020-10-30
    Sponsor Name:DAIICHI SANKYO, INC
    Full Title: A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3-1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC)
    Medical condition: Advanced or metastatic colorectal cancer (CRC) which is resistant, refractory, or intolerant to at least 2 prior lines of therapy, that must include all of the following agents: fluoropyrimidine, i...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000820-20 Sponsor Protocol Number: NVG111-101 Start Date*: 2020-10-30
    Sponsor Name:NovalGen Ltd
    Full Title: AN OPEN-LABEL, PHASE 1/2, FIRST IN HUMAN STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF NVG-111 IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA ...
    Medical condition: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA AND MANTLE CELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003684-35 Sponsor Protocol Number: R2810-ONC-1763 Start Date*: 2018-07-10
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients wit...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) PL (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-001698-89 Sponsor Protocol Number: Monet Start Date*: 2006-06-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen
    Medical condition: Early or locally advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003743-30 Sponsor Protocol Number: BEVPAC Start Date*: 2012-11-20
    Sponsor Name:Karolinska University Hospital
    Full Title: A prospective randomized Phase II study to identify predictive biomarkers and mechanisms of therapy resistance in patients with HER2-negative metastatic breast cancer (MBC) treated with the combina...
    Medical condition: Advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000661-19 Sponsor Protocol Number: CFEM345EGB07 Start Date*: 2005-11-04
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: Neoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5m...
    Medical condition: Postmenopausal women with ER and/or PgR positive primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000524-82 Sponsor Protocol Number: RMH CCR No 3107 Start Date*: 2008-10-09
    Sponsor Name:Royal Marsden Hospital
    Full Title: MESH: A Non-Randomised Phase II Trial of Methotrexate in Metastatic Colorectal Cancer with MSH2 Deficiency
    Medical condition: Metastatic colorectal cancer resistanct to standard chemotherapy with evidence of deficiency of the mismatch repair gene MSH2, either on immunohistochemistry of tumour histology or on testing of pe...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000306-70 Sponsor Protocol Number: 2009/07 Start Date*: 2008-01-29
    Sponsor Name:University of Dundee
    Full Title: The effect of metformin on biomarker activity in primary breast cancer
    Medical condition: Women with histologically proven operable primary, invasive breast cancer of ≥ 1cm in size. The study will involve women from the east of Scotland.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005018-47 Sponsor Protocol Number: 008-IRCC-10IIS-14 Start Date*: 2015-04-08
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial
    Medical condition: Cancers of Unknown Primary (CUP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073059 Malignant neoplasm of unknown primary site PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003483-32 Sponsor Protocol Number: FILO Start Date*: 2019-04-25
    Sponsor Name:FILO
    Full Title: BLINAtumomab after R-CHOP debulking therapy for patients with Richter Transformation.
    Medical condition: Richter transformation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003328-22 Sponsor Protocol Number: 56022473MDS2002 Start Date*: 2017-02-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplast...
    Medical condition: Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004985-27 Sponsor Protocol Number: HO139 Start Date*: 2016-09-29
    Sponsor Name:HOVON Foundation
    Full Title: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, foll...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014445-80 Sponsor Protocol Number: CP4055-306 Start Date*: 2010-06-23
    Sponsor Name:Clavis Pharma
    Full Title: A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia
    Medical condition: Late Stage Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066764 Acute myeloid leukaemia progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) ES (Ongoing) BE (Completed) PL (Completed) IT (Ongoing) GB (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000033-36 Sponsor Protocol Number: LYMRIT-37-01 Start Date*: 2012-10-18
    Sponsor Name:Nordic Nanovector ASA
    Full Title: A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.
    Medical condition: Non-Hodgkin B-cell lymphoma Part A: Relapsed indolent Non-Hodgkin B-cell lymphoma Part B: Relapsed follicular lymphoma Part C: Relapsed indolent Non-Hodgkin B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) FR (Prematurely Ended) ES (Prematurely Ended) HR (Completed) HU (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed) DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 13:18:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA